| Specialty Retail Industry | Consumer Discretionary Sector | Dr. Jonas Ekblom Ph.D. CEO | OTC PINK Exchange | SE0003613090 ISIN |
| DE Country | 5 Employees | - Last Dividend | - Last Split | - IPO Date |
Moberg Pharma AB (publ) operates as a pharmaceutical company with a global reach, focusing on the development and commercialization of medical products. Originally known as Moberg Derma AB (publ), the company underwent a name change in May 2013, signaling a broader focus within the pharmaceutical industry. Since its foundation in 2006, Moberg Pharma has been dedicated to addressing complex medical conditions, with its headquarters located in Bromma, Sweden. The company has successfully positioned itself in both European and international markets, including the United States, by emphasizing research, development, and commercialization of novel treatments.
A leading product in Moberg Pharma’s portfolio, MOB-015, has reached a pivotal stage in its development. This innovative treatment for nail fungus has successfully completed Phase III clinical trials, marking a significant milestone towards offering patients a new, effective solution for this common but challenging condition. MOB-015’s progress underlines Moberg Pharma AB's commitment to advancing dermatological care through rigorous research and development.